459.62
2.59 (0.57%)
| 前收盘价格 | 457.03 |
| 收盘价格 | 458.45 |
| 成交量 | 763,957 |
| 平均成交量 (3个月) | 1,679,734 |
| 市值 | 118,029,033,472 |
| 预期市盈率 (P/E Forward) | 20.20 |
| 价格/销量 (P/S) | 8.93 |
| 股市价格/股市净资产 (P/B) | 5.89 |
| 52周波幅 | |
| 利润日期 | 7 Aug 2025 |
| 营业毛利率 | -8.91% |
| 营业利益率 (TTM) | 37.22% |
| 稀释每股收益 (EPS TTM) | -3.80 |
| 季度收入增长率 (YOY) | 3.00% |
| 季度盈利增长率 (YOY) | -41.20% |
| 总债务/股东权益 (D/E MRQ) | 10.00% |
| 流动比率 (MRQ) | 2.65 |
| 营业现金流 (OCF TTM) | -980.30 M |
| 杠杆自由现金流 (LFCF TTM) | 2.63 B |
| 资产报酬率 (ROA TTM) | 11.77% |
| 股东权益报酬率 (ROE TTM) | -5.64% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Vertex Pharmaceuticals Incorpor | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.38 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Value |
| 内部持股比例 | 0.15% |
| 机构持股比例 | 97.64% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 553.00 (UBS, 20.32%) | 购买 |
| 中 | 476.50 (3.67%) | |
| 低 | 405.00 (RBC Capital, -11.88%) | 保留 |
| 平均值 | 477.29 (3.84%) | |
| 总计 | 9 购买, 5 保留 | |
| 平均价格@调整类型 | 385.82 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Evercore ISI Group | 11 Sep 2025 | 475.00 (3.35%) | 购买 | 397.37 |
| Canaccord Genuity | 06 Aug 2025 | 411.00 (-10.58%) | 保留 | 385.65 |
| Guggenheim | 06 Aug 2025 | 546.00 (18.79%) | 购买 | 385.65 |
| Wells Fargo | 06 Aug 2025 | 460.00 (0.08%) | 购买 | 385.65 |
| BMO Capital | 05 Aug 2025 | 530.00 (15.31%) | 购买 | 374.98 |
| Cantor Fitzgerald | 05 Aug 2025 | 485.00 (5.52%) | 购买 | 374.98 |
| HC Wainwright & Co. | 05 Aug 2025 | 478.00 (4.00%) | 购买 | 374.98 |
| 23 Jun 2025 | 550.00 (19.66%) | 购买 | 443.54 | |
| Morgan Stanley | 05 Aug 2025 | 439.00 (-4.49%) | 保留 | 374.98 |
| 20 Jun 2025 | 460.00 (0.08%) | 保留 | 440.87 | |
| RBC Capital | 05 Aug 2025 | 405.00 (-11.88%) | 保留 | 374.98 |
| 17 Jun 2025 | 420.00 (-8.62%) | 保留 | 441.99 | |
| Scotiabank | 05 Aug 2025 | 438.00 (-4.70%) | 保留 | 374.98 |
| Stifel | 05 Aug 2025 | 455.00 (-1.01%) | 保留 | 374.98 |
| Truist Securities | 05 Aug 2025 | 490.00 (6.61%) | 购买 | 374.98 |
| UBS | 05 Aug 2025 | 553.00 (20.32%) | 购买 | 374.98 |
| JP Morgan | 14 Jul 2025 | 517.00 (12.48%) | 购买 | 472.35 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合